Chandan Healthca

Why is Chandan Healthcare Ltd falling/rising?

As of 28-Aug, Chandan Healthcare Ltd's stock price is declining significantly, currently at 217.90, with a year-to-date drop of -32.86%. Despite strong debt servicing capabilities, negative recent performance and low investor interest indicate a bearish trend for the stock.

As of 28-Aug, Chandan Healthcare Ltd's stock price is falling, currently at 217.90, reflecting a change of -4.35 (-1.96%). The stock has underperformed significantly in the short term, with a 1-week decline of -5.61% compared to a minor decrease of -0.31% in the Sensex. Over the past month, the stock has also decreased by -5.43%, while the Sensex has risen by +0.79%. Year-to-date, the stock has plummeted by -32.86%, contrasting sharply with the Sensex's decline of only -7.48%.<BR><BR>Today's performance indicates that the stock is underperforming its sector by -2.53%. It is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. Additionally, there has been a significant drop in investor participation, with delivery volume on 27 August falling by -75.61% against the 5-day average, indicating a lack of interest from investors.<BR><BR>While the company has a strong ability to service its debt, as evidenced by a low Debt to EBITDA ratio of 0.94 times and healthy long-term growth in operating profit at an annual rate of 79.65%, these positive factors are overshadowed by recent negative results. The operating profit to interest ratio is at its lowest, and interest expenses are at their highest, which raises concerns about profitability. Furthermore, the lack of investment from domestic mutual funds, holding only 0% of the company, suggests a lack of confidence in the stock's valuation or business prospects.<BR><BR>Overall, the combination of poor recent performance, declining investor interest, and negative financial indicators contributes to the falling stock price of Chandan Healthcare Ltd.

Which are the latest news on Chandan Healthca?

Should I buy, sell or hold Chandan Healthcare Ltd?

What does Chandan Healthca do?

Chandan Healthcare Ltd operates advanced laboratories for pathological investigations in the hospital sector, with a market cap of INR 572 Cr and recent net sales of 76 Cr and net profit of 7 Cr as of March 2026. Established in 2003, it has a P/E ratio of 21.00 and a return on equity of 17.21%.

Overview: <BR>Chandan Healthcare Ltd operates state-of-the-art laboratories providing comprehensive pathological investigations in the hospital industry, categorized as a micro-cap company.<BR><BR>History: <BR>Chandan Healthcare Ltd was established on September 03, 2003. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 76 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 7 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 572 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 21.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.22 <BR>Return on Equity: 17.21% <BR>Price to Book: 3.38 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Chandan Healthca?

Chandan Healthca's peers include Shalby, GPT Healthcare, Unihealth Hosp, Aprameya Enginee, Lotus Eye Hospit, Vaidya Sane, Asarfi Hospital, and KMC Speciality. Chandan Healthca shows excellent management and growth, with a 1-year return of 3.98%, outperforming Shalby but underperforming Unihealth Hosp, which has the highest return at 326.01%.

Peers: The peers of Chandan Healthca are Shalby, GPT Healthcare, Unihealth Hosp, Aprameya Enginee, Lotus Eye Hospit, Vaidya Sane, Asarfi Hospital, and KMC Speciality.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare and Aprameya Enginee, while Good management risk is found at Shalby, Chandan Healthca, and KMC Speciality. Average management risk is present at Unihealth Hosp, Asarfi Hospital, and Vaidya Sane, while Below Average management risk is noted at Lotus Eye Hospit. In terms of Growth, Excellent growth is seen at Unihealth Hosp and Chandan Healthca, while Good growth is found at Asarfi Hospital and KMC Speciality. Below Average growth is observed at Shalby, GPT Healthcare, and Aprameya Enginee, while Lotus Eye Hospit and Vaidya Sane have Below Average growth. Good capital structure is noted at Shalby, Chandan Healthca, Aprameya Enginee, Lotus Eye Hospit, and KMC Speciality, while Excellent capital structure is found at GPT Healthcare and Unihealth Hosp.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Unihealth Hosp at 326.01%, while the lowest is Shalby at -25.06%. Chandan Healthca's 1-year return is 3.98%, which is higher than Shalby but lower than Unihealth Hosp. Additionally, peers such as Aprameya Enginee, Vaidya Sane, and KMC Speciality have a six-month return of 0.00%.

Are Chandan Healthcare Ltd latest results good or bad?

Chandan Healthcare Ltd's latest results show strong revenue and profit growth, with a net profit increase of 64.76% year-on-year and revenue growth of 38.32%. However, declining operating margins and negative cash flow raise concerns about long-term sustainability, suggesting caution for investors.

Chandan Healthcare Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹6.92 crores for Q4 FY26, which is a significant increase of 64.76% year-on-year and a 52.42% increase compared to the previous quarter. Additionally, revenue for the same quarter reached ₹75.58 crores, marking a robust 38.32% year-on-year growth and a sequential growth of 16.26%. This indicates strong demand and successful market penetration in the diagnostic services sector.<BR><BR>However, there are concerns regarding margin pressures. The operating margin decreased to 16.45% from 18.21% in the previous quarter, reflecting rising operational costs, particularly in employee expenses. This contraction in margins, coupled with negative operating cash flow of ₹29 crores due to a significant working capital build-up, raises questions about the sustainability of profitability moving forward.<BR><BR>Overall, while the revenue and profit growth are commendable, the decline in operating margins and cash flow challenges suggest caution for investors. The company is in a growth phase, but it needs to address these margin pressures to ensure long-term stability and profitability.

How big is Chandan Healthca?

As of 14th August, Chandan Healthcare Ltd has a market capitalization of 572.00 Cr, with recent net sales of 271.14 Cr and a net profit of 25.28 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Chandan Healthcare Ltd has a market capitalization of 572.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 271.14 Cr, while the sum of Net Profit for the same period is 25.28 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 122.60 Cr and Total Assets valued at 210.62 Cr.

How has been the historical performance of Chandan Healthca?

Chandan Healthca has experienced significant growth from March 2023 to March 2025, with net sales increasing from 136.89 Cr to 230.12 Cr and profit after tax rising from 3.59 Cr to 23.52 Cr, despite facing challenges in cash flow management. Total assets grew from 76.12 Cr to 210.62 Cr, indicating a solid financial position.

Answer:<BR>Chandan Healthca has shown significant growth in its financial performance over the past three years, particularly from March 2023 to March 2025.<BR><BR>Breakdown:<BR>In terms of net sales, Chandan Healthca increased its revenue from 136.89 Cr in March 2023 to 230.12 Cr in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 136.89 Cr to 230.12 Cr during the same period. The company's total expenditure also grew, from 127.51 Cr in March 2023 to 188.79 Cr in March 2025, with notable increases in raw material costs and employee costs. Operating profit, excluding other income, surged from 9.38 Cr in March 2023 to 41.33 Cr in March 2025, indicating improved operational efficiency. Profit before tax rose significantly from 5.01 Cr to 32.06 Cr, and profit after tax increased from 3.59 Cr to 23.52 Cr, showcasing robust profitability growth. The earnings per share (EPS) also improved markedly from 1.69 to 9.07 over the same period. On the balance sheet, total assets grew from 76.12 Cr in March 2022 to 210.62 Cr in March 2025, while total liabilities increased from 42.05 Cr to 56.88 Cr, indicating a solid asset base. Cash flow from operating activities showed a negative trend, moving from a positive 6.00 Cr in March 2022 to a negative 29.00 Cr in March 2025, although net cash inflow remained positive at 2.00 Cr by March 2025. Overall, Chandan Healthca's performance reflects a strong growth trajectory in sales and profitability, despite challenges in cash flow management.

Is Chandan Healthca overvalued or undervalued?

As of August 28, 2025, Chandan Healthcare is considered very expensive and overvalued with a PE ratio of 24.29 and an EV to EBITDA of 13.34, especially compared to peers like Apollo Hospitals and Max Healthcare, and has recently declined by 7.9% against a 2.32% drop in the Sensex, indicating it may not be a favorable investment.

As of 28 August 2025, Chandan Healthcare's valuation grade has moved from fair to very expensive, indicating a significant shift in its market positioning. The company is currently deemed overvalued based on its financial ratios, including a PE ratio of 24.29, an EV to EBITDA of 13.34, and an ROE of 84.79%. These figures suggest that the stock is trading at a premium compared to its earnings and operational efficiency.<BR><BR>In comparison to its peers, Chandan Healthcare's valuation metrics stand out, particularly when contrasted with Apollo Hospitals, which has a PE ratio of 70.56 and an EV to EBITDA of 36.30, and Max Healthcare, which has a PE ratio of 93.61. This highlights that Chandan Healthcare is not only overvalued but also significantly more expensive relative to its competitors in the hospital industry. Furthermore, the recent stock performance shows a decline of 7.9% over the past week, while the Sensex only fell by 2.32%, reinforcing the notion that Chandan Healthcare may not be a favorable investment at its current valuation.

Who are the top shareholders of the Chandan Healthca?

The top shareholders of Chandan Healthcare include Amaranita Holdings (India) Private Limited with 16.87%, 11 Foreign Institutional Investors holding 3.86%, and Negen Undiscovered Value Fund at 3.16%. Individual investors own 33.0% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Chandan Healthcare include several key players. The majority of the shares are held by promoters, with Amaranita Holdings (India) Private Limited being the largest promoter, holding 16.87%. Additionally, there are 11 Foreign Institutional Investors (FIIs) that collectively hold 3.86% of the company's shares. The highest public shareholder is Negen Undiscovered Value Fund, which holds 3.16%. Individual investors collectively own 33.0% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

When is the next results date for Chandan Healthca?

No Upcoming Board Meetings

Has Chandan Healthca declared dividend?

No Dividend History Available